Clinical Trial Update: Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating sacituzumab govitecan versus standard of care for previously treated extensive-stage small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 3 | Status: RECRUITING